stockrowBioXcel Therapeutics, Inc. (BTAIQ) vs IM Cannabis Corp. (IMCC)
- BioXcel Therapeutics, Inc. BTAIQ 0.01 0.00%
- IM Cannabis Corp. IMCC 0.59 0.00%
BioXcel Therapeutics, Inc. and IM Cannabis Corp. are both Drug Manufacturers Specialty & Generic companies. BioXcel Therapeutics, Inc. is the larger, with a market value of $2.3M against $980.0K — 2.4× the size. IM Cannabis Corp. grew revenue faster over the last twelve months: −12.0% against −14.5%. IM Cannabis Corp. has the higher net margin (−38.9% vs −9,549.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, IM Cannabis Corp. leads on 11 and BioXcel Therapeutics, Inc. on 4.
Valuation
| Metric | BTAIQ | IMCC | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| P/E | n/m | n/m | 20.55 |
| P/S | 0.41 | 0.01 | 2.08 |
| P/B | n/m | n/m | 1.79 |
| Price to free cash flow | n/m | n/m | 16.29 |
| EV/EBITDA | n/m | 0.01 | 12.22 |
| EV/Sales | 227.51 | 0.00 | 2.87 |
| Earnings yield | (37,900.00%) | (13,047.81%) | (15.94%) |
| Free cash flow yield | (16,806.60%) | (267.31%) | 0.00% |
Profitability
| Metric | BTAIQ | IMCC | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 53.10% | 12.62% | 53.51% |
| Operating margin | (6,054.72%) | (32.88%) | 0.00% |
| Net margin | (9,549.87%) | (38.92%) | (2.45%) |
| Free cash flow margin | (6,860.38%) | (1.47%) | 0.00% |
| Return on equity | 63.52% | 2,280.06% | (0.80%) |
| Return on assets | (259.62%) | (54.20%) | (1.67%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack